Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1738008

registered interest
date	29/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gene Therapies
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of (1) the progress in using, and (2) the suitability of, the Innovative Medicines Fund in providing NHS access to gene therapies in England.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL2124
answer	answer is ministerial correction date of answer 07/11/2024 answer text <p>The Innovative Medicines Fund (IMF) was launched in June 2022 and builds on the successful Cancer Drugs Fund to support patient access to the most promising new medicines, while further evidence is collected on their use to address clinical uncertainty. £340 million is available through the fund this financial year for the National Health Service to fund early access to the most promising treatments, including gene therapies, while additional data is collected that will inform a future National Institute for Health and Care Excellence (NICE) evaluation to decide whether the medicine should be routinely funded. The NICE has recommended two treatments for use through the IMF, both of which are gene therapies, which are:</p><ul><li>etranacogene dezaparvovec, for treating moderately severe or severe haemophilia B; and</li><li>exagamglogene autotemcel, for treating transfusion-dependent beta-thalassaemia in people aged 12 years old and over.</li></ul> answering member printed Baroness Merron question first answered 07/11/2024 16:10:23 answering member 347 label Biography information for Baroness Merron
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1738009

registered interest
date	29/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sickle Cell Diseases
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what discussions they have had with NHS England and the National Institute for Health and Care Excellence about access to innovative treatments for sickle cell disease.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL2125
answer	answer is ministerial correction date of answer 04/11/2024 answer text <p>Department officials regularly discuss a range of issues with colleagues in NHS England and the National Institute for Health and Care Excellence (NICE), including access to new and innovative treatments for a range of diseases and conditions.</p><p>The NICE makes evidence-based recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NICE is currently evaluating exagamglogene autotemcel within its licensed indication for treating sickle cell, and has not yet published final guidance.</p><p>The NICE will aim to publish guidance on any new, licensed treatment for sickle cell disease as soon as possible after licensing.</p> answering member printed Baroness Merron question first answered 04/11/2024 14:31:57 answering member 347 label Biography information for Baroness Merron
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1738010

registered interest
date	29/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to ensure that new dementia treatments can be deemed cost-effective by the National Institute for Health and Care Excellence, in the light of the investment required to scale up diagnostics.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL2126
answer	answer is ministerial correction date of answer 08/11/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NHS in England is legally required to fund NICE-recommended medicines, normally within three months of the publication of final guidance. The NICE only recommends medicines that offer additional health benefits to patients and their carers, and demonstrate value for money for the taxpayer.</p><p>The NICE is currently evaluating two new licensed disease-modifying treatments for Alzheimer’s disease and has been unable to recommend them in its draft guidance. The NICE concluded that the relatively small benefits they provide balanced against the overall cost of providing the treatments, including intensive monitoring for serious side effects, means that they cannot currently be considered good value for the taxpayer. However, the NICE has not yet published final guidance and will take the comments received in response to its draft guidance fully into account in developing its final recommendations.</p><p>A number of other disease-modifying treatments for dementia are in late-stage development and are expected to come to market in the next few years. To prepare for the new generation of dementia treatments in development, NHS England is working to ensure that diagnostic and treatment capacity, and clinical pathway redesign and investment are in place to support the adoption of any new licensed and NICE recommended treatments as soon as possible.</p><p>The Government will transform the NHS from a late diagnosis, late treatment health service, to one that catches illness earlier and prevents it in the first place. We will also put Britain at the forefront of transforming treatment for dementia by backing more research into the disease. Part of this will be ensuring that we support manufacturers to develop products that are potentially cost effective to implement, and that new treatments assessed as clinically and cost effective are rolled out in a safe and timely way.</p><p>The Department funds dementia research via the National Institute for Health and Care Research (NIHR). Alongside Alzheimer’s Research UK, Alzheimer’s Society, and the People’s Postcode Lottery, the NIHR is funding the Blood Biomarker Challenge which seeks to produce the clinical and economic data that could make the case for the use of a blood test in the NHS to support diagnosis of dementia.</p> answering member printed Baroness Merron grouped question UIN HL2127 question first answered 08/11/2024 13:11:38 answering member 347 label Biography information for Baroness Merron
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1738011

registered interest
date	29/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dementia
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to ensure that disease-modifying dementia treatments are available through the NHS.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL2127
answer	answer is ministerial correction date of answer 08/11/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. The NHS in England is legally required to fund NICE-recommended medicines, normally within three months of the publication of final guidance. The NICE only recommends medicines that offer additional health benefits to patients and their carers, and demonstrate value for money for the taxpayer.</p><p>The NICE is currently evaluating two new licensed disease-modifying treatments for Alzheimer’s disease and has been unable to recommend them in its draft guidance. The NICE concluded that the relatively small benefits they provide balanced against the overall cost of providing the treatments, including intensive monitoring for serious side effects, means that they cannot currently be considered good value for the taxpayer. However, the NICE has not yet published final guidance and will take the comments received in response to its draft guidance fully into account in developing its final recommendations.</p><p>A number of other disease-modifying treatments for dementia are in late-stage development and are expected to come to market in the next few years. To prepare for the new generation of dementia treatments in development, NHS England is working to ensure that diagnostic and treatment capacity, and clinical pathway redesign and investment are in place to support the adoption of any new licensed and NICE recommended treatments as soon as possible.</p><p>The Government will transform the NHS from a late diagnosis, late treatment health service, to one that catches illness earlier and prevents it in the first place. We will also put Britain at the forefront of transforming treatment for dementia by backing more research into the disease. Part of this will be ensuring that we support manufacturers to develop products that are potentially cost effective to implement, and that new treatments assessed as clinically and cost effective are rolled out in a safe and timely way.</p><p>The Department funds dementia research via the National Institute for Health and Care Research (NIHR). Alongside Alzheimer’s Research UK, Alzheimer’s Society, and the People’s Postcode Lottery, the NIHR is funding the Blood Biomarker Challenge which seeks to produce the clinical and economic data that could make the case for the use of a blood test in the NHS to support diagnosis of dementia.</p> answering member printed Baroness Merron grouped question UIN HL2126 question first answered 08/11/2024 13:11:38 answering member 347 label Biography information for Baroness Merron
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1737287

registered interest
date	28/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood: Medical Equipment
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the remarks by Baroness Merron on 9 October (HL Deb col 1995), whether the working group considering apheresis capacity intends to consult stakeholders, including (1) the Cell and Gene Therapy Catapult, and (2) the Advanced Therapy Treatment Centre network, prior to publishing its report.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL2078
answer	answer is ministerial correction date of answer 04/11/2024 answer text <p>The apheresis working group was established to address issues around apheresis capacity and improve the resilience of stem cell supply for the United Kingdom. The working group is currently in the evidence gathering phase ahead of publishing its report in spring 2025.</p><p>The group is comprised of stakeholders from apheresis users, commissioning bodies, patient representatives, and subject matter experts. Each member has a responsibility for keeping wider stakeholders informed. The Cell and Gene Therapy Catapult is already represented within the working group. The catapult is responsible for coordination of the Advanced Therapy Treatment Centre network. Through submissions from, and engagement with, the Cell and Gene Therapy Catapult, a report is in preparation on apheresis capacity across users to be discussed at the next working group meeting.</p> answering member printed Baroness Merron question first answered 04/11/2024 16:50:29 answering member 347 label Biography information for Baroness Merron
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1736357

registered interest
date	22/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Medical Treatments
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to their report The impact of patient age on clinical decision-making in oncology, published on 23 February 2012, what recent assessment they have made of the extent to which age is a factor in oncology treatment decisions.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL1902
answer	answer is ministerial correction date of answer 29/10/2024 answer text <p>The Department has made no recent assessment of the extent to which age is a factor in oncology treatment decisions. Each National Health Service patient will be offered the treatment their clinicians consider to be the most effective.</p> answering member printed Baroness Merron question first answered 29/10/2024 12:01:07 answering member 347 label Biography information for Baroness Merron
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1735564

registered interest
date	21/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Fractures: Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what estimate they have made of the cost savings that universal fracture liaison services will generate for the NHS through the prevention of secondary fractures.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL1820
answer	answer is ministerial correction date of answer 28/10/2024 answer text <p>Improving health outcomes for the 20 million people in the United Kingdom who live with a musculoskeletal condition, including osteoporosis, forms a key part of the Government’s missions to build a National Health Service fit for the future, cut waiting times, and kick-start economic growth.</p><p>Fracture Liaison Services (FLS) play an important role in fracture prevention, helping to prevent fragility fractures and support patients who sustain them. The Government has launched a public engagement exercise to help shape its 10-Year Health Plan, which will be underlined by three big shifts in healthcare, one of which is from treatment to prevention. Officials have been working closely with NHS England on how to ensure better quality and access to FLSs, including on how best to support systems.</p><p>The Government has not made a specific estimate or assessment of the cost savings, economic impacts, or hospital bed occupancy pressures referenced in the question.</p> answering member printed Baroness Merron grouped question UIN HL1821 HL1823 question first answered 28/10/2024 11:54:20 answering member 347 label Biography information for Baroness Merron
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1735565

registered interest
date	21/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Osteoporosis
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the impact of delayed osteoporosis diagnosis on hospital bed occupancy rates; and what assessment they have made of how fracture liaison services could mitigate those pressures.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL1821
answer	answer is ministerial correction date of answer 28/10/2024 answer text <p>Improving health outcomes for the 20 million people in the United Kingdom who live with a musculoskeletal condition, including osteoporosis, forms a key part of the Government’s missions to build a National Health Service fit for the future, cut waiting times, and kick-start economic growth.</p><p>Fracture Liaison Services (FLS) play an important role in fracture prevention, helping to prevent fragility fractures and support patients who sustain them. The Government has launched a public engagement exercise to help shape its 10-Year Health Plan, which will be underlined by three big shifts in healthcare, one of which is from treatment to prevention. Officials have been working closely with NHS England on how to ensure better quality and access to FLSs, including on how best to support systems.</p><p>The Government has not made a specific estimate or assessment of the cost savings, economic impacts, or hospital bed occupancy pressures referenced in the question.</p> answering member printed Baroness Merron grouped question UIN HL1820 HL1823 question first answered 28/10/2024 11:54:20 answering member 347 label Biography information for Baroness Merron
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1735566

registered interest
date	21/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Fractures: Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what recent discussions they have had with (1) NHS England, and (2) integrated care boards, regarding the provision of fracture liaison services.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL1822
answer	answer is ministerial correction date of answer 31/10/2024 answer text <p>Fracture Liaison Services (FLS) are a globally recognised care model for secondary fracture prevention. They can reduce the risk of refracture by up to 40% for people at risk of osteoporosis.</p><p>FLSs are commissioned by integrated care boards which are well-placed to make decisions according to local need. Officials have been working closely with NHS England on how to ensure better quality and access to FLSs, including on how best to support systems.</p> answering member printed Baroness Merron question first answered 31/10/2024 17:09:12 answering member 347 label Biography information for Baroness Merron
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1735567

registered interest
date	21/10/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Osteoporosis
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of (1) the economic impact of osteoporotic fractures on the working-age population, and (2) the effect of universal fracture liaison services on economic activity.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL1823
answer	answer is ministerial correction date of answer 28/10/2024 answer text <p>Improving health outcomes for the 20 million people in the United Kingdom who live with a musculoskeletal condition, including osteoporosis, forms a key part of the Government’s missions to build a National Health Service fit for the future, cut waiting times, and kick-start economic growth.</p><p>Fracture Liaison Services (FLS) play an important role in fracture prevention, helping to prevent fragility fractures and support patients who sustain them. The Government has launched a public engagement exercise to help shape its 10-Year Health Plan, which will be underlined by three big shifts in healthcare, one of which is from treatment to prevention. Officials have been working closely with NHS England on how to ensure better quality and access to FLSs, including on how best to support systems.</p><p>The Government has not made a specific estimate or assessment of the cost savings, economic impacts, or hospital bed occupancy pressures referenced in the question.</p> answering member printed Baroness Merron grouped question UIN HL1820 HL1821 question first answered 28/10/2024 11:54:20 answering member 347 label Biography information for Baroness Merron
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick